
Enhanced colonic peristalsis is possible with Motegrity, the only FDA-approved selective serotonin type 4 (5-HT4) receptor agonist for adults with CIC.1-4
Contraindications
HAPCs=high amplitude propagating contractions
In a pharmacodynamic study in patients with CIC, a single 2 mg dose of Motegrity increased the number of HAPCs during the first 12 hours vs. an osmotic laxative treatment.1
Treatment with Motegrity 4 mg once daily (2X max recommended dose of 2 mg) for 7 days increased the amplitude of HAPCs in healthy subjects without affecting colonic phasic activity vs. placebo.1
HAPCs=high amplitude propagating contractions
*Up to $90 max benefit per 30-day prescription; $270 max benefit per 90-day prescription. Terms and conditions apply. See link above for details.
View the results established in 6 clinical trials in 2484 patients with CIC.1
See trial dataContraindications
Warnings and Precautions
Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.
Adverse Reactions
Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.
Use in Specific Populations
INDICATION
Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Please click here for full Prescribing Information.
1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Takeda Pharmaceuticals America, Inc. 2. Emmanuel A, Cools M, Vandeplassche L, Kerstens R. Am J Gastroenterol. 2014;109(6):887-894. 3. Miner PB, Camilleri M, Burton D, et al. Neurogastroenterol Motil. 2016;28(9):1341-1348. 4. Enterostasis. Stedman's Online. https://stedmansonline.com/content.aspx?term=ENTEROSTASIS. Accessed February 25, 2019.